![]() |
市场调查报告书
商品编码
1355848
葡萄糖生物感测器市场规模 - 按类型、技术、最终用途、全球预测,2032-2032 年Glucose Biosensors Market Size - By Type, By Technology, By End-Use, Global Forecast, 2032-2032 |
在生物感测器技术不断创新的推动下,葡萄糖生物感测器市场规模预计从 2023 年到 2032 年将以超过 13% 的复合年增长率成长。
技术进步促进了更准确、更紧凑和用户友好的葡萄糖生物感测器的发展,从而提高了葡萄糖测量的精度,并增强了使用者的便利性和舒适度。例如,2023 年6 月,总部位于圣地牙哥的Dexcom 透露,计画在2024 年将新的葡萄糖感测技术产品推向美国市场。此外,持续的研发工作带来了具有成本效益的生物感测器,从而提高了医疗保健提供者的采用率糖尿病患者将扩大市场前景。
整个葡萄糖生物感测器市场根据类型、技术、最终用途和地区进行分类。
就类型而言,由于全球患者对第 1 型糖尿病的认识不断提高,持续血糖监测 (CGM) 领域的市场价值预计到 2032 年将获得显着增长。 2022 年,国际糖尿病联盟报告称,全球有 875 万人患有第 1 型糖尿病。此外,CGM 技术的不断进步带来了更准确、用户友好且更具成本效益的设备,从而促进了市场成长。
就最终用途而言,医院领域的葡萄糖生物感测器产业规模将在 2022 年产生大量收入,预计 2023 年至 2032 年复合年增长率将达到 13.8%。这一增长是由于糖尿病及其併发症的盛行率不断上升。根据 2021 年发表的研究,每年有近 25% 的第 1 型糖尿病患者和 30% 的第 2 型糖尿病患者入院治疗。医院环境对准确、即时血糖监测设备的需求也不断增加,以便能够及时介入并更好地控制血糖,最终改善患者的治疗结果。
到2022 年,欧洲在全球葡萄糖生物感测器市场中占据相当大的份额,并且由于医疗保健支出的增长和葡萄糖生物感测器技术的不断进步,预计2023 年至2032 年期间将以显着的复合年增长率增长。血糖监测设备的优惠报销政策和知名市场参与者的强大存在也有助于市场扩张。此外,消费者可支配收入的增加以及先进产品的增加预计将推动区域市场的成长。例如,2023 年 9 月,美敦力 (Medtronic) 宣布其简化版 Simplera CGM 获得了 CE 标誌批准,为其在欧洲的推出做好了准备。
Glucose Biosensors Market size is projected to grow at over 13% CAGR from 2023 to 2032, driven by the ongoing innovations in biosensor technology.
Technological advancements have led to the development of more accurate, compact, and user-friendly glucose biosensors to offer improved precision of glucose measurements and enhanced convenience and comfort for users. For instance, in June 2023, San Diego-based Dexcom revealed plans to bring a new glucose-sensing technology product to the U.S. market by 2024. Furthermore, the ongoing R&D efforts resulting in cost-effective biosensors, leading to higher adoption among healthcare providers and individuals with diabetes will augment the market outlook.
The overall glucose biosensors market is categorized based on type, technology, end-use, and region.
With respect to type, the market value from the continuous glucose monitoring (CGM) segment is poised to gain significant traction through 2032 owing to the increasing patient awareness levels regarding diabetes type 1 worldwide. In 2022, the International Diabetes Federation reported that 8.75 million individuals across the globe have type 1 diabetes. Furthermore, the rising advancements in CGM technology have led to more accurate, user-friendly, and cost-effective devices, adding to the market growth.
In terms of end-use, the glucose biosensors industry size from the hospitals segment generated substantial revenue in 2022 and is forecasted to expand at 13.8% CAGR from 2023-2032. The growth is due to the rising prevalence of people suffering from diabetes and its complications. According to study published in 2021, nearly 25% of patients suffering from diabetes type 1 and 30% with diabetes type 2 are admitted to hospitals every year. The demand for accurate, real-time glucose monitoring devices in hospital settings is also on the rise for enabling timely interventions and better glycemic control for ultimately improving patient outcomes.
Europe held sizable share of the global glucose biosensors market in 2022 and is poised to grow at notable CAGR from 2023-2032 attributed to the growing healthcare expenditure and rising technological advancements in glucose biosensors. Favorable reimbursement policies for glucose monitoring devices and the strong presence of prominent market players are also contributing to the market expansion. Additionally, the rising disposable incomes of consumers coupled with the increasing availability of advanced products is projected to boost the regional market growth. For instance, in September 2023, Medtronic announced that its simplified Simplera CGM received the CE mark approval, setting it up for its introduction in Europe.